A private equity firm retained a CRA expert to assess the reasonableness of the expected purchase price of a company designed to exploit certain literary rights for motion pictures, television, and the stage. The analysis resulted in a $40 million reduction in the purchase price offered by the private equity firm.
Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...